Abstract Primary ciliary dyskinesia (PCD) is a rare, autosomal recessive disorder of motile cilia that leads to chronic respiratory disease. Current estimate for the prevalence is ∼1 in 15,000-20,000 individuals in the USA; this number is likely to change with increased awareness and improved diagnostic methods. There has been a striking increase in interest in the disease in recent years, leading to an increased understanding of the phenotype. The use of genetic testing has greatly aided the diagnosis of PCD and further helped the understanding of the pathogenesis of the disease. In parallel, the establishment of longitudinal clinical studies and the establishment of disease registries are helping to understand the natural history of the disease; all of which will help in developing clinical trials and better treatment guidelines. This review will focus on recent advances in our understanding of this interesting disease after a brief general overview.
Introduction
Primary ciliary dyskinesia, or PCD, is a recessively inherited genetic disorder of ciliary biogenesis, ultrastructure, and function, leading to a constellation of symptoms, including neonatal respiratory distress, lifelong oto-sino-pulmonary disease, organ laterality defects, and male infertility. The incidence is estimated to be approximately 1 in 15,000 to 20,000 individuals. Primary ciliary dyskinesia was previously known as Kartagener's syndrome as a triad of bronchiectasis, sinusitis, and situs inversus [1] . Later, it was noted that the cilia were stiff, immotile, and with defined ultrastructural abnormalities, and thus, the term Bimmotile cilia syndrome^was coined [2] . It was further recognized that ciliary motility in PCD is variable, can be motile, dyskinetic, and uncoordinated-hence the term Bciliary dyskinesia^ [3] . The Bprimary^label is intended to differentiate the inherited disease (PCD) from ciliary abnormalities due to other causes, usually inflammation and infection. There have been significant recent advances in the field. The majority of new knowledge has been in improved definitions of the presenting features and the longitudinal course of the clinical phenotype, refining diagnostic criteria and in the discovery of novel genetic mutations. The PCD Foundation and patient registries have been established, and clinical trials have begun. Better evidence-based therapies should follow [4] . There has also been a significant increase in interest in bronchiectasis, also with patient registries and translational studies, including patients with PCD [5] . These developments will translate into better treatments for all patients with Bnoncystic fibrosis (CF) bronchiectasis^in the near future. There have been several excellent reviews of the disease in general; this review article will focus mainly on highlighting the advances that have been made in PCD in more recent years, from pertinent recent literature [ non-motile cilia. Normal motile cilia are comprised of a complex of related proteins, with nine outer doublets and a central pair (B9 + 2^). Each of the outer doublets includes alpha and beta tubulin monomers with outer and inner dynein arms. These arms contain enzymes for ATP hydrolysis, causing conformational changes of the related proteins which cause ciliary movement. The structure is stabilized via nexin links and radial spokes extending to the central pair. Approximately 200 cilia per epithelial cell beat in a coordinated, synchronous fashion to effect mucociliary clearance. Some specialized motile cilia have a similar peripheral structure to the normal motile cilia but lack the central pair of microtubules. These cilia move in a rotary motion and are responsible, during early embryogenesis, for normal human left right asymmetry. Situs inversus occurs in a random fashion in PCD, with ∼50 % of patients having thoracic and abdominal mirror image organ placement [13] . Heterotaxy may occur as dextrocardia or abdominal situs inversus alone, polysplenia, divided hepatic lobes, and in a small but significant percent of individuals, complex congenital heart disease [14] .
It can thus be seen that mutations in genes encoding for ciliary proteins may result in a variety of heterogeneous clinical manifestations, although there are clinical symptoms which are universal to all patients with classic disease [15] . A history of lifelong rhino-sino-pulmonary symptoms is key. This includes neonatal respiratory distress, chronic wet productive cough, recurrent troublesome ear infections, and chronic nasal congestion and sinusitis [7••] . Patients generally have evidence of obstructive lung disease in later life, with radiographic evidence of bronchiectasis and chronic sinusitis [16] . Bronchiectasis is a universal feature of adult patients with PCD, although it may not be evident in children. Typical airway flora include Hemophilus influenza, Staphylcoccus aureus, Pseudomonas aeruginosa, and nontuberculous mycobacteria (NTM) [7••, 15] . Older patients commonly have had resection surgery [17] . Less commonly pectus excavatum and scoliosis may feature. The diagnosis of PCD requires a multi-faceted approach, starting with an increased awareness that a lifelong history of respiratory symptoms is central to the diagnosis (conversely, it is unlikely that an adult with onset of symptoms in the third or fourth decade of life has PCD) [7••] . Traditionally, treatment for patients affected by PCD has followed standard approaches applied to patients with cystic fibrosis and other forms of bronchiectasis [11•] .
Recent advances in PCD General national and international developments
An exciting development in the last decade has been the development of networks and consortia, which allows a collaborative effort among centers with a broad range of expertise, and translational studies of large numbers of patients. PCD research has benefitted greatly from the development of the Genetic Disorders of Mucociliary Clearance Consortium ( G D M C C ) ( h t t p s : / / w w w. r a r e d i s e a s e s n e t w o r k . org/cms/GDMCC). The GDMCC is a subset of the Rare Diseases Clinical Research Network (RDCRN), involving studies of rare diseases with impairments in mucociliary clearance, with PCD being the prototypic example. At the time of writing, in addition to 9 GDMCC PCD sites, there are 16 additional PCD sites in the process of accreditation, expanding the network of PCD centers with expertise in diagnosis, treatment, and research to 25 sites across North America. Sites collaborate on data gathering, recruitment of patients, and cross-sectional and longitudinal studies of the disease. Since its development, there has been a rapid dissemination of published information, with n = 53 manuscripts published by the GDMCC from 2006 to 2015 on a variety of subjects. In parallel, the creation of the PCD Foundation has facilitated patient education and a feeling of belonging to a patient and advocacy community (http://www.pcdfoundation. org/en/finding-a-cure/pcd-clinical-center). The PCD foundation is a not-for-profit organization, which was developed in 2002 by patients and parents to raise awareness of PCD, establish family education days, encourage patients to be proactive about their health and participate in research, and to fund raise for future research (akin to the fledgling Cystic Fibrosis Foundation in the 1950s). The PCD Foundation work with GDMCC has led to the development of the PCD Clinical and Research Centers Network (CRCN). The goal of the CRCN is to provide a reliable diagnosis, consistent high-quality, and appropriate care and allow comprehensive data collection through the PCD registry. An example of the collaborative GDMCC efforts is a longitudinal observation of patients with PCD aged 0-18 years over 5 years to examine agerelated progression of disease, age-related acquisition of bacteria, with age groupings correlated to ciliary ultrastructural defect and genetic mutations [18•] . These kinds of studies will yield important data on disease evolution from several contexts. Internationally, similar efforts are occurring; BESTCILIA is a research consortium comprised of ten European clinical centers and two US clinical centers with the goal of improving the clinical practice in PCD care through standardized care protocols and diagnostic testing as well as observational and randomized control trials (http://bestcilia.eu). A later iteration of this effort in Europe is BEAT-PCD (http://www.beatpcd.org/). As more centers join these networks and participate in clinical diagnostics and care, as well as translational research, publications related to PCD will likely increase further-for example, a simple recent PubMed search of Bprimary ciliary dyskinesia^yields a list of n = 561 publications for the years 2011-2016 (Tables 1 and 2 ).
Diagnosis of PCD
It is critical to confirm the presence of a compatible clinical phenotype prior to pursuing PCD diagnostic testing. This may sound self-evident, but patients with PCD may escape detection for lack of a thorough history (usually that of lifelong symptoms). Similarly, patients may be referred for specialty tests without such a lifelong history or missing other key historical components such as otitis or sinusitis. Recent work involving larger numbers of patients ascertained via the above-described registries and programs have allowed refinement of the diagnostic features of PCD. It cannot be overemphasized that the clinical features of PCD present at an early age. For example, neonatal respiratory distress is seen in more than 80 % of PCD patients by 24 h of life and manifests as increased work of breathing, tachypnea, and radiographic abnormalities including atelectasis of the upper and middle lobes [6••, 19, 20] . Year-round daily wet cough and nasal congestion are present in infancy and persist throughout adulthood. Recurrent otitis media with effusion also presents early in life. Pan-sinusitis is seen in almost all PCD patients via sinus imaging. Recurrent lower respiratory infections are seen in over 80 % of individuals with PCD, and by adulthood, all PCD patients have evidence of bronchiectasis [6••, 15] . Organ situs status as discussed above is useful diagnostically when present, less so when absent. The four criteria-defined clinical features of laterality defect; unexplained neonatal respiratory distress; early-onset, year-round wet cough; and early-onset, year-round nasal congestion are highly predictive of PCD with odd ratios ranging from 3.1 to 7.7. Sensitivity and specificity based on two criteria-defined clinical features are 0.80 and 0.72, respectively [7••] . In the recently published PCD Foundation Consensus Recommendations, the presence of at least two or more of these clinical features should prompt PCD diagnostic testing. Based on the combination of a compatible clinical phenotype with positive diagnostic testing, the diagnosis of PCD can be made. PCD diagnostic testing should occur at a specialized center with extensive experience with PCD. Nasal nitric oxide (nNO) levels in patients with PCD are low (<77 nL/min) relative to normal values (mean 287 nL/min with a range of 125-867 nL/min) [21•] . This makes nNO a useful screening test for PCD if testing is performed properly. Using a threshold of <77 nL/min, nNO testing has a sensitivity of 98 % and specificity of >99.9 %. Although traditionally nasal scrape samples for electron microscopic studies of ciliary ultrastructure have been regarded as the mainstay of a PCD diagnosis, it has become clear in recent years that these tests cannot be relied on because of the frequency of false positives and false negatives and the technical challenges in performing the test reliably and reproducibly [12••] . The saccharin test has no place in the diagnosis of PCD in the modern era.
Molecular genetics
Unlike in cystic fibrosis where many possible mutations in one gene can result in clinical disease (locus heterogeneity), many genes with multiple possible mutations result in PCD (locus and allele heterogeneity). While this complicated early searches for molecular mutations resulting in PCD, recent years have seen a dramatic gene mutation discovery [12••] . As an example, in 2012, PCD-causing mutations were described in only 14 genes. Through exome sequencing, PCDcausing mutations in an additional 23 genes have been identified [12••, 22, 23] . It is estimated that 65-70 % of patients with PCD can now be identified as having 2 mutations in one • Prior to considering diagnostic testing, close attention should be paid to a careful history, looking for the phenotypic characteristics of PCD (for example, lifelong symptoms) in patients with consistent presenting features. Nasal NO and genetics have emerged as being most useful diagnostically; nasal ciliary samples for electron microscopy and the nasal saccharin test are not currently recommended for diagnosis.
• The disease course is generally heterogeneous, and for the most part milder than CF over time, although some patients do develop severe disease.
• Sputum microbiology data are critical to guide disease therapies.
• Close monitoring is warranted, particularly imaging and lung function studies.
of 36 published genes. Considerable progress has been made towards the creation of a multi-gene panel of PCD genes for commercial testing at a reasonable cost, and these efforts will continue, such that gene testing for patients suspected of having PCD based on a strong phenotype is rapidly becoming feasible. For in depth reading of the specific genes involved, and their correlates to ciliary structure, function, and clinical phenotype, the reader is referred to a recent excellent overview on the topic [12••] .
Clinical course of PCD
A number of recently published studies have addressed the longitudinal course of PCD. This development in disease description is important, as an early report suggested a noteworthy decline in lung function that might be amenable to early intervention [24] . A cross-sectional study of lung function as related to patient age was published in 2004, in what was to date the largest number of pediatric and adult patients with definite (Bclassic^) PCD, and showed that the decline in FEV1 as patient grow older is probably not as steep as in CF (0.8 % per year for FEV1% predicted) [15] . It was also noted that despite a perception as a mild disease, some patients have severe airflow obstruction, even at a young age, sufficient to cause hypoxia and right heart failure or require lung transplantation. Bronchiectasis is present in 50-70 % of older children, and all adults over 30 years of age, usually in a dependent fashion (middle and lower lobes, unlike CF, where the upper lobes are usually the first affected areas of lung) [25] . Several longitudinal studies have been more recently published. Data from n = 20 clinically stable children (at the time of the measures) with PCD in France over a median time period of 15.4 years, showing significant declines in all lung function parameters, related to (z scores) to simultaneously worsening computed tomogram (CT) scores. Of note, 70 % of patients had bronchiectasis at a median age of 8.7 years, similar to the earlier study [15, 26] . A larger study from the national PCD center in Denmark (where monitoring and treatment protocols have been rigorously followed for decades) looked at n = 74 adults and children with PCD over a median of 9.5 years showed a deterioration in most patients from an early age, although with some variation in individual patients [27] . Of significance, neither earlier diagnosis (many pre-school children already had sub-normal lung function at first measure), or quite aggressive and frequent treatment schedules, did not seem to make a difference in regard to the decline in lung function over time. The authors concluded that PCD is a disease that Bposes a serious threat to and with much variation in the course lung function even at an early age^ [27] . A large UK study of n = 151 adults with PCD over a median followup of 7 years showed much variation in age at diagnosis (from birth to the eight decade of life), with worse lung function evident in older patients at the time of diagnosis [28•] . Like the French study, and not surprisingly, worse CT scores were associated with lower lung function, with Pseudomonas aeruginosa as an additional risk factor. A possible correlation between disease severity and ciliary abnormalities was also noted, echoing one other study suggesting a genotypephenotype relationship (since genetics are tightly bound to the ciliary abnormality) [18•] . Like other studies, a wide range of organisms was noted to occur in PCD, including Hemophilus influenza, gram negatives, and mycobacteria [15] . These data underscore the critical aspect of regular monitoring of sputum cultures in patients with PCD (and all forms of bronchiectasis). Indeed, it was recently emphasized at the first International Bronchiectasis Meeting (http://worldbronchiectasis-conference.com) that patients with bronchiectasis are commonly seen without any sputum culture data, and thus, it is impossible to devise a rational short-or long-term anti-microbial strategy for such patient (especially if P. aeruginosa or mycobacteria are present). Additionally, late diagnosis was noted in many patients, suggesting that an increased awareness of PCD is required, at a minimum obtaining a history of lifelong disease, and most often all the classic features of the disease as noted earlier in this review [28•] . As with earlier studies, the disease does not appear to inflict a similar mortality (or lung transplant need) as CF (3.3 vs 11 %). Another lung function-focused study also from the UK noted that in a fairly large (n = 150) cohort of children with PCD followed at a national center, many (25 %) failed to recover lost lung function after a treated exacerbation [29] . These data suggest a need for better prevention and of course better acute treatments. Finally, a study from France looked at a cohort of adults aged 18-77 years with PCD (n = 78 over a median of ∼8 years) [30] . Again, lower lung function with P aeruginosa and worse CT scores was noted, with perhaps a signal for worse disease in females. While annual decline in FEV1 was lower than in CF (13.4 vs 54 ml/year), a small number of patients (n = 9) had very severe disease, requiring oxygen or non-invasive ventilation, or being considered for, or had had a lung transplant. These new data, while not perfect, at least inform the development of clinical guidelines (discussed below). The field looks forward to larger longitudinal multi-center studies in the next few years that will likely prove as beneficial as existing long-term CF registry studies [31] . Finally, although not specific to PCD, the recent development of the Bronchiectasis Severity Index (BSI) may help identify patients especially at risk [32] .
Outcome measures; PCD quality of life tools
While objective clinical data such as lung function and sputum monitoring are critical in PCD, other outcome measures are important. Like most chronic diseases, PCD has a significant effect on quality of life. Patients regularly report that cough is one of the most troublesome symptoms they experience, while at the same time recognizing that cough compensates to some extent for defective mucociliary clearance [33] . Studies in bronchiectasis are therefore beginning to incorporate disease-specific quality-of-life measures into research studies [34] . While the St. George's Respiratory Questionnaire (SGRQ) and Leicester Cough Questionnaire (LCQ) have been useful tools, neither of these patient-related outcomes are specific to PCD-omitting, for example, fertility issues, ear, nasal, and sinus-type symptoms. To help address this, a PCDspecific quality of life questionnaire (QOL-PCD) has been developed with significant patient input from the USA, UK, and Canada [35••] . This is the first comprehensive healthrelated quality of life questionnaire that is patient reported in PCD and addresses how Bpatients survive feel and functionâ s per the FDA definition. Thus, the QOL-PCD was developed to assess emotional, physical social well-being, and symptoms and thus how the illness and interventions affect the individual over time. It encompasses questions directed towards PCD symptoms, especially upper airway disease, hearing, and has major focus on the effects of cough on QOL [16] . The questionnaire has already been translated into multiple languages and is undergoing psychometric testing to assess reliability and validity, having been developed to account for cross-cultural populations. The preliminary study was tested in cognitive studies in adults with PCD in the UK and North America, with multi-national psychometric field studies to follow [35••] . Ultimately, as with all such novel outcome measures, reliability and validity studies will follow. A similar QOL-PCD along similar lines has been developed for pediatric age group patients [36] .
Treatment protocols
There have been no randomized clinical trials of new therapies yet conducted in PCD, other than the occasional pilot study [33, 37] . Most of the data for treatment of PCD are extrapolated from studies looking at patients with CF and other forms of bronchiectasis [38] . Some Bstate-of-the-art^PCD-specific consensus statements or literature review-based summaries have been published, to try to standardize patient monitoring and treatment, pending better data from registries and clinical trials, one with an official Bblessing^from the PCD Foundation [6••, 11•, 12••, 39] . The mainstay of these treatments includes rigorous preventative care to include regular monitoring of lung function, airway microbiology, airway clearance, and pathogen-targeted anti-microbial therapy. In reality, this boils down to seeing patients and measuring lung function two to four times a year to detect sub-clinical declines in airway health and sending sputum for gram stain and culture (to include NTM) at the same frequency. Chest radiographs and CTs can be performed as clinically indicated, but at a minimum, a CT at baseline is reasonable for diagnostic purposes (all adults are likely to have bronchiectasis) and to assess extent of disease, with chest radiographs every 2 to 4 years. These clinical data allow direct aggressive preventive care and early interventions with appropriate antibiotics (systemic if necessary). This requires dedication and attention to detail on the part of the clinician taking care of the patient and ideally should be someone with experience in the management of bronchiectasis, or cystic fibrosis, or both, and ideally a pediatric or adult pulmonologist with a Bholistic,^team-based philosophy. Accredited PCD Foundation clinical centers and CF centers are best positioned to take this expert rigorous approach [6••] .
Airway clearance and exercise
Airway clearance is an integral part of treatment protocols for bronchiectasis, including PCD. While there are no data on exactly what regime or technique or device to use, educational sessions in regard to proper airway clearance techniques, device usage, and exercise should be a part of every clinic visit if at all possible, with more intense sessions early in the process to emphasize to the patient the importance of these as an integral part of the self-management of this chronic disease [40, 41] . Exercise has anecdotally been the best airway clearance of many patients with bronchiectasis, and recent studies do show a beneficial effect of exercise for short-term symptoms, as well as decreasing number of exacerbations [42] . Among patients with PCD, one study showed exercise to be a more potent bronchodilator than beta agonists, and another suggests that exercise could be associated with improved lung function [43] . Most experts recommend a regime of regular daily airway clearance tailored to the individual, using various huffing/breathing techniques, postural drainage/clapping, and exercise with or without one of the many available devices or vests.
Mucolytic agents, airway hydration therapies, and anti-inflammatory agents A commonly used mucolytic in patients with cystic fibrosis is nebulized recombinant human deoxyribonucease (rhDNase), which works by lysing neutrophilic DNA. This, however, has not shown to be beneficial in patients with non-CF bronchiectasis and may even be harmful [44] . It is not therefore recommended in patients with PCD. Other inhaled (nonantibiotic) medications commonly used in patients with bronchiectasis include hypertonic saline and mannitol, bronchodilators, and inhaled corticosteroids. None of these have been studied specifically in patients with PCD; however, systematic reviews of studies in non-CF bronchiectasis generally conclude decreased exacerbations and modest improvements in lung function occur after use with hypertonic saline and mannitol [11•, 38, 45] . There are no data supporting use of inhaled steroids or bronchodilators in PCD, although of course in practice, many patients use such agents, especially with coexistent asthma. Most clinicians in practice advocate the use of hypertonic saline as a regular, relatively inexpensive inhaled medicine to augment airway clearance in patients with PCD, if necessary in combination with a bronchodilator to modulate the possibility of side effects such as wheeze/ airway irritation. In regard to macrolide therapy as an antiinflammatory (with perhaps some anti-bacterial actions), the best data come from non-CF bronchiectasis, such that macrolides (usually azithromycin) have become standard therapy for patients with PCD, except in the case of side effects (usually gastrointestinal) or patients expectorating mycobacteria from their airways. Three recent randomized controlled trials have shown that patients with non-CF bronchiectasis have significantly decreased numbers of exacerbations, rates of exacerbations, and prolonged time to first exacerbation, with modest improvements in lung function and quality of life [46] [47] [48] . A study specific to PCD is currently underway in Europe [4] .
Antibiotic therapies; acute vs chronic usage
Broadly speaking, antibiotic therapy (Bsputum culture results directed^) is a mainstay in the management of what is, after all, a chronic infectious disease of the lung [15] . Exacerbations tend to follow a pattern similar to all forms of bronchiectasis, with increase in cough, sputum production (including hemoptysis), loss of energy and appetite, chest pain, dyspnea, and a loss of lung function. Whether oral or systemic antibiotics and what choices of drugs are used depends on the predominant organisms cultured and its sensitivity patterns and according to expert consensus opinion [11•, 49] . A common point of confusion is whether to use inhaled antibiotics for an acute exacerbation. Generally, inhaled antibiotics are used in bronchiectasis as a preventive Bmaintenance^therapy, rather than as rescue therapy, except perhaps in milder cases, in conjunction with an oral quinolone, much as is done in CF. Inhaled aminoglycosides (tobramycin or gentamicin) can be considered in patients with chronic carriage of gram-negative organisms in their sputum, although such a recommendation is extrapolated from studies in cystic fibrosis and non-CF bronchiectasis [11•, 50] . Generally, for treatment of gram-negative organism associated moderate to severe exacerbations, combined, synergistic, systemic therapy is recommended [11•] .
Miscellaneous
There are very few indications for surgery in PCD, although studies have shown that in the past such surgery has frequently been performed in childhood or early adulthood in patients with PCD [15] . A small retrospective study in Cyprus looking at patients who had lobectomies prior to diagnosis of PCD showed that as compared to their non-surgical cohorts, patients who had had surgery had lower lung function with fewer clinical symptoms [17] . The upper respiratory tract is nearly universally involved in all patients with PCD with chronic rhino-sinusitis and chronic otitis media. Treatment is symptom focused and includes sinus irrigations, topical steroids, topical surfactant use, antibiotics, and endoscopic sinus surgery [16] . Unfortunately, most of these approaches have not yet been studied in patients with PCD, and while they are frequently used, and should plausibly be beneficial, further data are required to provide a solid recommendation [16] . Given the risk of conductive hearing loss, frequent audiology evaluations and management of chronic ear infections are important. Ventilation tubes however hold a risk of chronic otorrhea; therefore, risk and benefits should be discussed in detail with an ENT physician and are definitely not recommended by some expert panels [16, 39] .
Conclusion
These are very exciting times for a disease that has lurked in the medical shadows for decades after its first description, often mentioned with only a few lines in the major medical textbooks. This review will likely change rapidly over the next few years, as rigorous data emerges on disease pathophysiology longitudinal data allowing better disease monitoring and rigorous evidence-based guidelines for disease and treatment.
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